StocksFundsScreenerSectorsWatchlists
INVA

INVA - Innoviva Inc Stock Price, Fair Value and News

15.25USD-0.04 (-0.26%)Delayed as of 28 Mar 2024, 11:03 am ET

Market Summary

INVA
USD15.25-0.04
Delayedas of 28 Mar 2024, 11:03 am
-0.26%

INVA Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

INVA Stock Price

View Fullscreen

INVA RSI Chart

INVA Valuation

Market Cap

966.7M

Price/Earnings (Trailing)

5.38

Price/Sales (Trailing)

3.11

EV/EBITDA

5.72

Price/Free Cashflow

6.87

INVA Price/Sales (Trailing)

INVA Profitability

EBT Margin

62.52%

Return on Equity

26.63%

Return on Assets

14.45%

Free Cashflow Yield

14.55%

INVA Fundamentals

INVA Revenue

Revenue (TTM)

310.5M

Rev. Growth (Yr)

30.45%

Rev. Growth (Qtr)

27.63%

INVA Earnings

Earnings (TTM)

179.7M

Earnings Growth (Yr)

696.58%

Earnings Growth (Qtr)

-25%

Breaking Down INVA Revenue

52 Week Range

11.1115.39
(Low)(High)

Last 7 days

1.6%

Last 30 days

-4.9%

Last 90 days

-7.0%

Trailing 12 Months

37.7%

How does INVA drawdown profile look like?

INVA Financial Health

Current Ratio

9.03

Debt/Equity

0.66

Debt/Cashflow

0.32

INVA Investor Care

Buy Backs (1Y)

7.19%

Diluted EPS (TTM)

2.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023326.1M320.9M315.7M310.5M
2022376.7M361.6M346.5M331.3M
2021350.6M364.3M378.1M391.9M
2020284.5M299.4M322.3M336.8M
2019263.8M260.8M264.9M261.0M
2018229.1M237.6M250.7M261.0M
2017149.9M176.0M191.3M217.2M
201671.2M93.0M112.8M133.6M
201516.1M25.8M38.4M53.9M
20145.5M6.5M7.5M8.4M
20135.3M5.1M4.8M4.5M
2012145.3M140.3M135.3M5.6M
201124.3M24.4M24.4M24.5M
201000024.2M
200900024.4M

Tracking the Latest Insider Buys and Sells of Innoviva Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 05, 2024
ronsheim matthew
acquired
189,988
14.88
12,768
see remarks
Mar 05, 2024
zhen marianne
acquired
159,990
14.88
10,752
chief accounting officer
Mar 05, 2024
basso stephen
acquired
179,988
14.88
12,096
chief financial officer
Feb 20, 2024
ronsheim matthew
sold (taxes)
-12,750
15.8
-807
see remarks
Feb 20, 2024
zhen marianne
sold (taxes)
-45,219
15.8
-2,862
chief accounting officer
Jan 18, 2024
ronsheim matthew
sold (taxes)
-25,680
16.05
-1,600
see remarks
Nov 20, 2023
zhen marianne
sold (taxes)
-10,678
13.62
-784
chief accounting officer
Nov 15, 2023
zhen marianne
sold
-153,810
13.9903
-10,994
chief accounting officer
Nov 15, 2023
zhen marianne
acquired
-
-
302
chief accounting officer
Aug 18, 2023
zhen marianne
sold (taxes)
-10,707
13.64
-785
chief accounting officer

1–10 of 50

Which funds bought or sold INVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-2.32
123,485
722,442
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-0.07
20,408,100
107,668,000
-%
Mar 05, 2024
GERBER, LLC
new
-
550,172
550,172
0.50%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
102
19,872,900
33,094,700
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.94
94,515
518,028
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
67,000
349,000
-%
Feb 20, 2024
Pacific Center for Financial Services
unchanged
-
610
3,208
-%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
reduced
-93.26
-1,785,830
162,004
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
32.41
11,289
29,289
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
2.82
169,000
796,000
-%

1–10 of 43

Are Funds Buying or Selling INVA?

Are funds buying INVA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own INVA
No. of Funds

Unveiling Innoviva Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
putnam investments llc
9.8%
6,270,413
SC 13G/A
Feb 13, 2024
renaissance technologies llc
6.47%
4,144,447
SC 13G/A
Feb 13, 2024
vanguard group inc
10.47%
6,712,443
SC 13G/A
Feb 09, 2024
dimensional fund advisors lp
7.0%
4,516,999
SC 13G
Jan 22, 2024
blackrock inc.
16.1%
10,349,116
SC 13G/A
May 15, 2023
sarissa capital management lp
10.54%
6,904,000
SC 13D/A
Feb 14, 2023
putnam investments llc
7.6%
5,329,107
SC 13G
Feb 13, 2023
renaissance technologies llc
6.06%
4,229,607
SC 13G/A
Feb 10, 2023
blackrock inc.
15.2%
10,611,839
SC 13G/A
Feb 09, 2023
vanguard group inc
10.13%
7,072,212
SC 13G/A

Recent SEC filings of Innoviva Inc

View All Filings
Date Filed Form Type Document
Mar 22, 2024
10-K/A
Annual Report
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 05, 2024
10-K/A
Annual Report
Mar 04, 2024
SC 13D/A
13D - Major Acquisition
Feb 29, 2024
8-K
Current Report
Feb 29, 2024
10-K
Annual Report
Feb 22, 2024
4
Insider Trading

Peers (Alternatives to Innoviva Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Innoviva Inc News

Latest updates
MarketBeat • 39 hours ago
InvestorsObserver • 25 Mar 2024 • 04:14 pm
Defense World • 22 Mar 2024 • 09:50 am
MarketBeat • 22 Mar 2024 • 03:21 am
InvestorsObserver • 15 Mar 2024 • 05:52 pm
Moneyshow.com • 2 months ago

Innoviva Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue27.6%86.0067.0067.0066.0066.0067.0081.0094.0010898.0095.0093.0090.0089.0079.0079.0076.0066.0064.0055.0080.00
Costs and Expenses231.8%25.00-18.6975.0035.00130-21988.0045.00-------------
Operating Expenses-------21926.0012.0077.00-25.314.006.006.004.003.003.002.005.004.003.003.00
  S&GA Expenses-8.1%26.0029.0024.0020.0017.0028.0012.006.003.003.004.006.005.003.003.003.002.005.004.003.003.00
  R&D Expenses-40.9%2.004.0015.0013.0010.0012.0014.006.000.000.000.000.000.001.001.00------
EBITDA Margin129.8%0.74*0.32*0.94*0.97*0.96*1.27*0.76*1.04*1.22*1.35*1.21*1.20*---------
Interest Expenses35.4%6.004.004.004.004.005.004.003.005.005.005.005.005.005.005.005.005.005.005.005.005.00
Income Taxes-108.8%-0.344.005.006.004.0057.00-0.907.0011.0021.0025.0020.0016.009.0020.0016.0012.0011.0010.009.00-196
Earnings Before Taxes-28.8%61.0086.006.0041.00-64.6928620.0045.0056.0012313612991.0050.0011895.0070.0058.0056.0049.0073.00
EBT Margin189.3%0.63*0.22*0.84*0.87*0.87*1.18*0.68*0.96*1.14*1.27*1.12*1.11*---------
Net Income-25.0%62.0082.001.0035.00-10.3122921.0038.00-6.05103111110-6.6242.0098.0079.0058.0047.0046.0040.00269
Net Income Margin69.4%0.58*0.34*0.80*0.84*0.84*-0.09*0.88*0.84*0.81*0.84*0.70*0.69*---------
Free Cashflow-24.3%33.0044.0038.0026.009.0016.0079.0098.0098.0097.0085.0084.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets4.7%1,2441,1881,1181,1301,2311,3281,1381,1079268877891,0881,000922880788725676642590548
  Current Assets12.9%34430532429644433.0040031831414.0014837334217.00500467431367318252199
    Cash Equivalents7.5%19418017314429130128421720213543.0028324647941335227817314265.0062.00
  Inventory0.5%41.0041.0047.0050.0056.0071.00---------------
  Net PPE33.8%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
  Goodwill0%18.0018.0015.0028.0027.0016.006.006.00-------------
  Current Liabilities5.4%38.0036.0039.0038.001357.001261096.009.005.004.006.007.005.003.005.003.007.004.006.00
  Long Term Debt0.1%446446445445444444443443395392390388386383381379377389387385383
    LT Debt, Current-----96.0096.0096.0096.00-------------
    LT Debt, Non Current0.1%446446445445444444443443395392390388386383381379377389387385383
Shareholder's Equity7.6%675627555561566641565552526492394697608535493406342284247200159
  Retained Earnings71.0%-25.19-86.72-168-170-204-136-402-403-456-466-538-627-722-775-804-880-946-992-1,032-1,069-1,103
  Additional Paid-In Capital-1.3%1,0931,1071,1171,1251,1641,1711,1841,1831,2641,2621,2621,2611,2611,2601,2601,2591,2591,2581,2581,2571,256
Shares Outstanding-1.7%63.0064.0065.0066.0069.0070.0070.0070.0082.0069.0095.00101---------
Minority Interest-------17716611189.0064.0062.0068.0049.0036.0026.0029.0017.0020.0012.005.00
Float---731,927---924---840,847---877---1,006--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-24.3%33,25643,94238,18225,6848,89915,69079,03598,10298,38196,71184,61484,10785,28074,55879,79473,48166,90557,40256,49676,65561,777
  Share Based Compensation-11.4%1,2771,4421,5201,5981,3263,7171,350954554542470451447441375435488489474605486
Cashflow From Investing80.1%-5,151-25,888--35,722-8,67897,722-2,522-143,156-19,905-90,021-26,394-315,481-8,500-7,00016,04451,994-15,93720,107-74,167-45,594
Cashflow From Financing-31.6%-14,589-11,082-9,206-136,962-10,001-96,163-9,73560,331-12,066-4,861-414,260-21,310-2,505-12.00-11,628-15,640-13,749-10,471198246-2,381
  Dividend Payments-------------------3.008.008.00
  Buy Backs32.2%14,63611,0719,28640,7358,503----------------

INVA Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Total revenue$ 310,463$ 331,339$ 391,866
Expenses:   
Selling, general and administrative98,23263,53816,187
Research and development33,92241,432576
Amortization of acquired intangible assets21,7845,5810
Gain on sale of Theravance Respiratory Company, LLC ("TRC")0(266,696)0
Loss on extinguishment of debt020,6620
Changes in fair values of equity method investments, net(77,392)161,749(84,392)
Changes in fair value of equity and long-term investments, net(11,129)(8,462)(6,638)
Interest and dividend income(15,818)(6,369)(1,839)
Interest expense19,15715,78919,070
Other expense, net4,9693,3733,626
Total expenses, net116,36544,390(53,410)
Income before income taxes194,098286,949445,276
Income tax expense, net14,37666,68776,439
Net income179,722220,262368,837
Net loss attributable to noncontrolling interests06,341102,983
Net income attributable to Innoviva stockholders$ 179,722$ 213,921$ 265,854
Basic net income per share attributable to Innoviva stockholders$ 2.75$ 3.07$ 3.24
Diluted net income per share attributable to Innoviva stockholders$ 2.2$ 2.37$ 2.87
Shares used to compute Innoviva basic and diluted net income per share:   
Shares used to compute basic net income per share65,43569,64482,062
Shares used to compute diluted net income per share86,87695,24894,310
Royalty revenue   
Revenue:   
Total revenue$ 238,846$ 311,645$ 391,866
Net product sales   
Revenue:   
Total revenue60,61719,6940
Expenses:   
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)41,04013,7930
License revenue   
Revenue:   
Total revenue11,00000
License   
Expenses:   
Cost of license revenue$ 1,600$ 0$ 0

INVA Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 193,513$ 291,049
Accounts receivable14,4549,401
Receivables from collaboration arrangements69,62154,672
Inventory40,73755,897
Prepaid expenses21,63029,559
Other current assets4,2642,933
Total current assets344,219443,511
Property and equipment, net483170
Equity method investments116,54639,154
Equity and long-term investments444,432363,859
Capitalized fees paid, net83,78497,607
Right-of-use assets2,5363,265
Goodwill17,90526,713
Intangible assets230,335252,919
Other assets3,2674,299
Total assets1,243,5071,231,497
Current liabilities:  
Accounts payable6,7172,939
Accrued personnel-related expenses7,0208,022
Accrued interest payable3,4224,359
Deferred revenue1,2772,094
Convertible subordinated notes due 2023, net of issuance costs096,193
Income tax payable0154
Other accrued liabilities19,69821,207
Total current liabilities38,134134,968
Long-term debt, net of discount and issuance costs446,234444,180
Other long-term liabilities71,87070,918
Deferred tax liabilities, net5635,771
Income tax payable, long-term11,7519,872
Commitments and contingencies (Note 13)
Stockholders' equity:  
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding00
Common stock: $0.01 par value, 200,000 shares authorized, 69,307 and 69,188 issued and outstanding as of December 31, 2023 and December 31, 2022 respectively633692
Treasury stock: at cost, 32,005 shares as of December 31, 2023 and 2022(393,829)(393,829)
Additional paid-in capital1,093,3401,163,836
Accumulated deficit(25,189)(204,911)
Total stockholders' equity674,955565,788
Total liabilities and stockholders' equity$ 1,243,507$ 1,231,497
INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
 WEBSITEwww.inva.com
 EMPLOYEES101

Innoviva Inc Frequently Asked Questions


What is the ticker symbol for Innoviva Inc? What does INVA stand for in stocks?

INVA is the stock ticker symbol of Innoviva Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Innoviva Inc (INVA)?

As of Wed Mar 27 2024, market cap of Innoviva Inc is 966.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INVA stock?

You can check INVA's fair value in chart for subscribers.

What is the fair value of INVA stock?

You can check INVA's fair value in chart for subscribers. The fair value of Innoviva Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Innoviva Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INVA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Innoviva Inc a good stock to buy?

The fair value guage provides a quick view whether INVA is over valued or under valued. Whether Innoviva Inc is cheap or expensive depends on the assumptions which impact Innoviva Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INVA.

What is Innoviva Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, INVA's PE ratio (Price to Earnings) is 5.38 and Price to Sales (PS) ratio is 3.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INVA PE ratio will change depending on the future growth rate expectations of investors.